Frontlight ResearchEarly access
TerminatedPhase 3
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia
Key facts
- Who runs it
- Neurocrine Biosciences
- Where
- Atlanta, Coral Gables, and San Jose, United StatesSee the 3 sites
- Trial code
- Status
- Terminated
- Phase
- Phase 3
- People taking part
- 8 people enrolled
- Started
- 5 Jan 2023
- Ended
- 8 Nov 2023
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Valbenazine
- Placebo
- Record updated
- 12 November 2024
- Why it stopped
- Study ATS3020 was closed due to business reasons. Neurocrine Biosciences will continue to conduct study ATS3019 (NCT05110157). There were no unexpected safety findings for this compound that motivated the decision.
Who can take part
- Age
- 13 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Medically confirmed diagnosis of schizophrenia
- Participant is receiving a stable regimen of background antipsychotic medication
- Plasma levels for at least 1 of the participant's antipsychotic medications must be detectable by an available assay
- Participant is an outpatient with stable symptomatology
- Participant must have an adult informant (for example, a family member, relative, partner, social worker, caseworker, residential facility staff, or nurse)
Who cannot take part
- Prior (within 6 months of Screening) or concomitant use of any vesicular monoamine transporter 2 (VMAT2) inhibitor (that is, valbenazine, reserpine, tetrabenazine, deutetrabenazine); or a history of intolerance to VMAT2 inhibitors
- Has a history of treatment resistant schizophrenia
- Have a clinically significant unstable medical condition in the judgement of the investigator or any laboratory value outside the normal range that is considered by the investigator to be clinically significant at the screening visit
Where in United States
- Atlanta, GeorgiaHospital not named in the registry
- Coral Gables, FloridaHospital not named in the registry
- San Jose, CaliforniaHospital not named in the registry
About the trial
What the trial wants to find out
This primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.
The 2 groups in the trial
- ValbenazineTreatment being tested
Valbenazine once daily
- PlaceboPlacebo, for comparison
Placebo once daily
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects With Schizophrenia
- Record updated
- 12 November 2024